UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 3.377

Sortiert nach

The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma

The New England journal of medicine, 2002-06, Vol.346 (25), p.1937-1947

2002

Volltextzugriff (PDF)

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

Blood, 2007-03, Vol.109 (5), p.1857-1861

2007

Volltextzugriff (PDF)

Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six Genes

The New England journal of medicine, 2004-04, Vol.350 (18), p.1828-1837

2004

Volltextzugriff (PDF)

Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5

Blood, 2007-01, Vol.109 (2), p.478-485

2007

Volltextzugriff (PDF)

A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma

Clinical cancer research, 2008-10, Vol.14 (20), p.6697-6703

2008

Volltextzugriff (PDF)

Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia

Journal of clinical oncology, 2005-08, Vol.23 (22), p.5027-5033

2005

Volltextzugriff (PDF)

Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival

Blood, 2006-12, Vol.108 (13), p.4178-4186

2006

Volltextzugriff (PDF)

Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype

Haematologica (Roma), 2010-08, Vol.95 (8), p.1342-1349

2010

Volltextzugriff (PDF)

FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma

Blood, 2006-10, Vol.108 (8), p.2720-2725

2006

Volltextzugriff (PDF)

Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients

Blood, 2007-04, Vol.109 (7), p.2773-2780

2007

Volltextzugriff (PDF)

Rituximab plus CHOP (R-CHOP) overcomes bcl-2—associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)

Blood, 2003-06, Vol.101 (11), p.4279-4284

2003

Volltextzugriff (PDF)

Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori–positive gastric diffuse large B-cell lymphomas

Blood, 2012-05, Vol.119 (21), p.4838-4844

2012

Volltextzugriff (PDF)

Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience

Annals of oncology, 2006-01, Vol.17 (1), p.123-130

2006

Volltextzugriff (PDF)

Highly effective treatment of acquired immunodeficiency syndrome–related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology

Blood, 2003-06, Vol.101 (12), p.4653-4659

2003

Volltextzugriff (PDF)

Treatment for Primary CNS Lymphoma: The Next Step

Journal of clinical oncology, 2000-09, Vol.18 (17), p.3144-3150

2000

Volltextzugriff (PDF)

Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab

British journal of haematology, 2006-09, Vol.134 (5), p.475-484

2006

Volltextzugriff (PDF)

Diffuse large B‐cell lymphoma: clinical implications of extranodal versus nodal presentation – a population‐based study of 1575 cases

British journal of haematology, 2004-01, Vol.124 (2), p.151-159

2004

Volltextzugriff (PDF)

Diffuse Large B-Cell Lymphoma: Clinical and Biological Characterization and Outcome According to the Nodal or Extranodal Primary Origin

Journal of clinical oncology, 2005-04, Vol.23 (12), p.2797-2804

2005

Volltextzugriff (PDF)

Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma

Blood, 2003-09, Vol.102 (6), p.1989-1996

2003

Volltextzugriff (PDF)

Results of Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue in 22 Patients With Refractory or Recurrent Primary CNS Lymphoma or Intraocular Lymphoma

Journal of clinical oncology, 2001-02, Vol.19 (3), p.742-749

2001

Volltextzugriff (PDF)

Phase II Study of Enzastaurin, a Protein Kinase C Beta Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Journal of clinical oncology, 2007-05, Vol.25 (13), p.1741-1746

2007

Volltextzugriff (PDF)

Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation : Results of a phase II trial

Cancer, 2005-10, Vol.104 (8), p.1661-1667

2005

Volltextzugriff (PDF)

Characteristics and Outcome of Diffuse Large B-Cell Lymphoma in Hepatitis C Virus–Positive Patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte Programs

Journal of clinical oncology, 2006-02, Vol.24 (6), p.953-960

2006

Volltextzugriff (PDF)

Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab

Annals of oncology, 2004-01, Vol.15 (1), p.129-133

2004

Volltextzugriff (PDF)

Primary diffuse large B-cell lymphoma of the stomach

Critical reviews in oncology/hematology, 2007-07, Vol.63 (1), p.65-71

2007

Volltextzugriff (PDF)

1 – 25 von 3.377

Suche als RSS-Feed

Aktive Filter

ThemaMedical Sciences

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(3.260)
Mit Volltextzugriff
(3.062)

Publikationsform

Artikel
(3.375)
magazinearticle
(2)

Sprache

Englisch
(3.377)
Japanisch
(574)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Biological And Medical Sciences
(3.375)
Humans
(3.244)
Science & Technology
(3.130)
Life Sciences & Biomedicine
(3.126)
Hematologic And Hematopoietic Diseases
(2.250)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(2.175)
Male
(2.028)
Female
(1.972)
Middle Aged
(1.707)
Oncology
(1.458)
Aged
(1.448)
Adult
(1.292)
Hematology
(1.234)
Pharmacology. Drug Treatments
(1.212)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(1.133)
Antineoplastic Agents
(1.024)
Lymphoma, Large B-Cell, Diffuse - Drug Therapy
(833)
Lymphoma, B-Cell - Drug Therapy
(819)
Treatment Outcome
(806)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(367)
British Journal Of Haematology
(252)
Journal Of Clinical Oncology
(217)
Leukemia
(161)
Annals Of Oncology
(152)
Clinical Cancer Research
(134)
Cancer
(121)
Cancer Research
(97)
International Journal Of Hematology
(93)
American Journal Of Hematology
(85)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six Genes

Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5

A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma

Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia

Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival

Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype

FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma

Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients

Rituximab plus CHOP (R-CHOP) overcomes bcl-2—associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)

Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori–positive gastric diffuse large B-cell lymphomas

Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience

Highly effective treatment of acquired immunodeficiency syndrome–related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology

Treatment for Primary CNS Lymphoma: The Next Step

Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab

Diffuse large B‐cell lymphoma: clinical implications of extranodal versus nodal presentation – a population‐based study of 1575 cases

Diffuse Large B-Cell Lymphoma: Clinical and Biological Characterization and Outcome According to the Nodal or Extranodal Primary Origin

Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma

Results of Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue in 22 Patients With Refractory or Recurrent Primary CNS Lymphoma or Intraocular Lymphoma

Phase II Study of Enzastaurin, a Protein Kinase C Beta Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation : Results of a phase II trial

Characteristics and Outcome of Diffuse Large B-Cell Lymphoma in Hepatitis C Virus–Positive Patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte Programs

Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab

Primary diffuse large B-cell lymphoma of the stomach

Aktive Filter

Suchergebnisse filtern